A federal appeals court has agreed to hear an interlocutory appeal of Shire LLC’s patent infringement case against Sandoz Inc. over hyperactivity disorder drug Adderall XR that raises a question of whether a patentee is precluded from relitigating claim construction issues determined in a previous case.
The details can be read here.
The order can be read here.
No comments:
Post a Comment